Roivant Sciences Ltd. Common Shares
Symbol: ROIV (NASDAQ)
14.30
▲ (3.81%) 0.525
Company Description:
Roivant Sciences Ltd is a commercial-stage biopharmaceutical company dedicated to improving the delivery of healthcare to patients. It also incubates discovery-stage companies and health technology startups complementary to its biopharmaceutical business. Its drug candidate VTAMA (tapinarof) is a treatment of plaque psoriasis in adult patients and is in its commercial stage. The other drug candidates in their different stages of development are; Batoclimab, IMVT-1402, Brepocitinib, Namilumab, and others.
Key Stats
- Today's Open: $13.83
- Today's High: $14.385
- Today's Low: $13.795
- Today's Volume: 8.04M
- Yesterday Close: $13.77
- Yesterday High: $13.82
- Yesterday Low: $13.395
- Yesterday Volume: 13.12M
- Last Min Volume: 15.33K
- Last Min High: $14.293
- Last Min Low: $14.275
- Last Min VWAP: $14.27634
Company Profile
- Name: Roivant Sciences Ltd. Common Shares
- Website: https://www.roivant.com
- Listed Date: 2021-10-01
- Location: LONDON,
- Market Status: Active
- CIK Number: 0001635088
- SIC Code: 2834
- SIC description: PHARMACEUTICAL PREPARATIONS
- Market Cap: $9.40B
- Round Lot: 100
- Outstanding Shares: 682.88M
- Asset Type: CS
RECENT FILINGS FOR ROIV
| Filing Date | Filing Type | Format |
|---|---|---|
| 2025-09-05 | 4 | View |
| 2025-09-03 | 8-K | View |
| 2025-09-02 | 4 | View |
| 2025-08-22 | 4 | View |
| 2025-08-22 | 4 | View |
| 2025-08-20 | 144 | View |
| 2025-08-14 | SCHEDULE 13G/A | View |
| 2025-08-14 | SCHEDULE 13G/A | View |
| 2025-08-11 | 10-Q | View |
| 2025-08-11 | 8-K | View |
| 2025-08-07 | SCHEDULE 13G | View |
| 2025-08-06 | SCHEDULE 13G/A | View |
| 2025-08-01 | 4 | View |
| 2025-08-01 | 4 | View |
| 2025-07-30 | 4 | View |
| 2025-07-29 | 3 | View |
| 2025-07-29 | ARS | View |
| 2025-07-29 | DEF 14A | View |
| 2025-07-29 | DEFA14A | View |
| 2025-07-23 | 4 | View |
Latest News on ROIV